kaishi tochitatemono company, ltd.

420 lexington avenue
suite 2656
new york, new york 10170

NYS Entity Status
ACTIVE

NYS Filing Date
OCTOBER 02, 2014

NYS DOS ID#
4645558

County
NEW YORK

Jurisdiction
JAPAN

Registered Agent
NONE

NYS Entity Type
FOREIGN BUSINESS CORPORATION

Name History
2014 - KAISHI TOCHITATEMONO COMPANY, LTD.









Buffer

submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • N.Y. Company Accused of Running Bitcoin Ponzi Scheme
    Thursday Sep 21, 2017

    The CFTC has accused New York company Gelfman Blueprint of operating a bitcoin-related Ponzi scheme, in the regulator’s first fraud-related action involving the cryptocurrency.

    Source: The Wall Street Journal: Technology: What's News
  • NY insurance company dragged into Wells Fargo scandal
    By Kevin Dugan - Tuesday Aug 1, 2017

    The New York insurance company that wrote policies for 800,000 questionable Wells Fargo auto loans has been dragged into the bank’s latest scandal. National General Insurance was named in a class-action lawsuit filed against the bank — for allegedly unduly profiting from $80 million in collateral protection insurance that the drivers didn’t need — and...

    Source: New York Post: Business
  • NY Times sees jump in digital subscription revenue
    By Reuters - Thursday Jul 27, 2017

    The New York Times said on Thursday its digital subscription revenue overtook print advertising revenue for the first time — a key milestone in the 166-year old publisher’s efforts to transform itself into a digital media powerhouse. The company’s shares rose as much as 7 percent to their highest since the 2008 financial crisis as...

    Source: New York Post: Business
  • Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
    By Ben Fidler - Tuesday Sep 12, 2017

    Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]

    Source: Xconomy New York
  • Budget Bus Lines Flout the Rules With Little Consequence
    By PATRICK McGEEHAN and WINNIE HU - Monday Sep 25, 2017

    Even after deadly crashes like the one in Queens last week, discount bus companies are often able to stay in business and evade serious penalties.

    Source: NYT > Home Page